title: Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab.
abstract: Lung cancer is the leading cause of cancer death in the United States. The majority of patients present with advanced stage disease, and treatment with standard cytotoxic chemotherapy agents have been shown to provide a modest improvement in survival, reduce disease-related symptoms, and improve quality of life. However, with standard chemotherapy treatments the prognosis is poor with the majority of patients dying in less than a year from diagnosis. Treatment with standard chemotherapy agents has reached a therapeutic plateau, and recent investigations have focused on therapies that target a specific pathway within the malignant cell or related to angiogenesis. The most promising of the targeted therapies are agents that target the process of angiogenesis. Bevacizuamab is a monoclonal antibody that binds to circulating vascular endothelial growth factor (VEGF)-A, and prevents binding of VEGF to vascular endothelial growth factor receptors, thus inhibiting activation of the VEGF pathway and angiogenesis. A recent phase III trial of first-line treatment of advanced non-small cell lung cancer revealed a statistically significant improvement in response, progression-free survival, and overall survival with the combination of bevacizumab and standard chemotherapy in comparison to standard chemotherapy alone. Bevacizumab is the only targeted therapy that has been shown to improve survival when combined with standard chemotherapy in the first-line setting.
authors.affiliation: Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, NC, USA.
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Stinchcombe
references.citation: Eur J Cardiothorac Surg. 1997 Oct;12(4):535-41
references.pmid: 9370395
references.citation: Clin Cancer Res. 2007 Apr 1;13(7):1961-70
references.pmid: 17404076
references.citation: Oncogene. 1990 Apr;5(4):519-24
references.pmid: 2158038
references.citation: J Clin Oncol. 2005 Sep 1;23(25):5892-9
references.pmid: 16043829
references.citation: J Clin Oncol. 2000 Jun;18(12):2354-62
references.pmid: 10856094
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: Oncologist. 2005 May;10(5):345-56
references.pmid: 15851793
references.citation: J Clin Oncol. 2004 May 1;22(9):1589-97
references.pmid: 15117980
references.citation: N Engl J Med. 2005 Jun 23;352(25):2589-97
references.pmid: 15972865
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: Br J Cancer. 2003 Jun 16;88(12):1979-86
references.pmid: 12799646
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1336-43
references.pmid: 11230476
references.citation: JAMA. 2003 Oct 22;290(16):2149-58
references.pmid: 14570950
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: Cancer Res. 1993 Oct 1;53(19):4727-35
references.pmid: 8402650
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: Blood. 2001 Sep 15;98(6):1904-13
references.pmid: 11535528
references.citation: Lung Cancer. 2005 Feb;47(2):253-9
references.pmid: 15639724
references.citation: J Clin Oncol. 2001 May 15;19(10):2626-37
references.pmid: 11352954
references.citation: Eur J Cancer. 1996 Dec;32A(14):2451-60
references.pmid: 9059333
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1545-52
references.pmid: 17442998
references.citation: J Clin Oncol. 2005 May 10;23(14):3270-8
references.pmid: 15886314
references.citation: Nat Med. 2001 Sep;7(9):987-9
references.pmid: 11533692
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: JAMA. 2004 Jul 28;292(4):470-84
references.pmid: 15280345
references.citation: Ann Oncol. 2010 Mar;21(3):540-547
references.pmid: 19833819
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: J Physiol. 2001 May 15;533(Pt 1):263-72
references.pmid: 11351033
references.citation: J Pathol. 1995 Sep;177(1):57-63
references.pmid: 7472781
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2184-91
references.pmid: 15169807
references.citation: Eur J Cancer. 2000 Mar;36(5):601-9
references.pmid: 10738124
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references.pmid: 15329413
references.citation: Science. 1983 Feb 25;219(4587):983-5
references.pmid: 6823562
references.citation: J Clin Oncol. 2001 Feb 1;19(3):843-50
references.pmid: 11157038
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2544-55
references.pmid: 15753462
references.citation: J Neurooncol. 1999;44(3):275-81
references.pmid: 10720207
references.citation: J Natl Cancer Inst. 2005 Apr 6;97(7):499-506
references.pmid: 15812075
references.citation: Cancer Metastasis Rev. 1990 Nov;9(3):171-4
references.pmid: 1705485
references.citation: Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4258s-4262s
references.pmid: 15217970
references.citation: J Clin Oncol. 2006 Jan 10;24(2):217-27
references.pmid: 16365183
references.citation: J Clin Oncol. 2004 Mar 1;22(5):785-94
references.pmid: 14990633
references.citation: Cancer Res. 2005 Feb 1;65(3):671-80
references.pmid: 15705858
references.citation: J Clin Oncol. 2000 May;18(10):2095-103
references.pmid: 10811675
references.citation: Science. 2006 May 26;312(5777):1171-5
references.pmid: 16728631
references.citation: J Clin Oncol. 2006 Oct 1;24(28):4539-44
references.pmid: 17008692
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Cancer. 2006 May 15;106(10):2208-17
references.pmid: 16604529
references.citation: Cancer. 1992 Sep 1;70(5):1102-10
references.pmid: 1515985
references.citation: Clin Lung Cancer. 2006 Jul;8(1):18-21
references.pmid: 16870041
references.citation: Semin Cancer Biol. 1992 Apr;3(2):65-71
references.pmid: 1378311
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1335-43
references.pmid: 11870177
references.citation: N Engl J Med. 2004 Jan 22;350(4):351-60
references.pmid: 14736927
references.citation: Lung Cancer. 2001 Nov;34(2):233-41
references.pmid: 11679182
references.citation: Cancer Immunol Immunother. 1999 Oct;48(7):396-400
references.pmid: 10501853
references.citation: J Clin Oncol. 2004 Mar 1;22(5):777-84
references.pmid: 14990632
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579-86
references.pmid: 1417831
references.citation: J Thorac Cardiovasc Surg. 1999 Apr;117(4):736-43
references.pmid: 10096969
references.citation: Nat Rev Cancer. 2003 Jun;3(6):401-10
references.pmid: 12778130
references.citation: J Clin Oncol. 2001 Feb 1;19(3):851-6
references.pmid: 11157039
references.citation: Am J Pathol. 1995 May;146(5):1029-39
references.pmid: 7538264
references.citation: J Clin Oncol. 2004 Jan 15;22(2):330-53
references.pmid: 14691125
references.citation: J Clin Oncol. 1989 Nov;7(11):1748-56
references.pmid: 2681557
references.citation: J Clin Oncol. 2005 Feb 1;23(4):842-9
references.pmid: 15681529
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: J Clin Oncol. 2005 May 10;23(14):3243-56
references.pmid: 15886312